SOURCE: DNAPrint Genomics, Inc.

July 31, 2006 07:00 ET

DNAPrint Pharmaceuticals Completes the Development of an Analytical Method That Will Be Used for the Development of PT-401

SARASOTA, FL -- (MARKET WIRE) -- July 31, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that its subsidiary, DNAPrint Pharmaceuticals, Inc., has completed the development of the so-called "Western blot" method, an analytical procedure that identifies a protein according to its interaction with a specific antibody, a significant step in the development of its PT-401-based proprietary drug to treat anemia.

"The method ensures the identification of PT-401 and meets the requirements of the Food and Drug Administration for a successful Investigational New Drug filing," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics and the Company's DNAPrint Pharmaceuticals subsidiary.

"The method assures that the development of PT-401 is moving forward," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We are making excellent progress in developing a successful treatment for anemia."

PT-401 is a "Super EPO," a more powerful form of Erythropoietin, a well-known drug used to treat anemia. PT-401 is a potential competitor in an EPO market that currently exceeds $10 billion and is rapidly growing.

DNAPrint Pharmaceuticals is developing "theranostic" genetic test/drug combinations designed to improve a drug's efficacy and reduce potential side effects. "Our genetic ancestry panel will help identify patient population groups most susceptible to the drug's potential toxic side effects," Mr. Gabriel said. "We believe our genetic ancestry technology offers a distinct, competitive advantage in its application to pharmaceutical development and theranostics. This is where Dr. Frudakis' and our scientific team's work on understanding genetic ancestry will really pay off."

DNAPrint Genomics is utilizing its EPOFusion™ model to simulate the cellular and molecular dynamics influenced by the administration of the Erythropoietin class of protein drugs in anemia treatments. EPOFusion™ models the interaction of PT-401 -- a novel 2-copy (dimer) form of Erythropoietin -- with the cells that trigger the production of new red blood cells. EPOFusion™ can be manipulated to test hundreds of conditions and variables by simulating what occurs in the whole blood cell production process. The EPOFusion™ model has already identified important differences between PT-401 and currently marketed drugs or drugs in development by other companies. This type of information may provide a competitive advantage and is critical for transparent regulatory filings and effective physician education upon FDA approval of a drug for clinical testing.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. ( is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (Erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941 366-3400

    Ron Stabiner
    The Wall Street Group, Inc.